TOKYO, Feb 18 (Reuters) - Merck KGaA (MRCG.DE: Quote, Profile, Research) and Takeda Pharmaceutical Co Ltd (4502.T: Quote, Profile, Research) have decided to terminate the development of cancer drug matuzumab after its mid-stage trials failed to meet expectations, Takeda said on Monday.
